Company Profile

Virion Systems Inc (AKA: VSI)
Profile last edited on: 11/4/13      CAGE: 45GC3      UEI:

Business Identifier: Pediatric Infectious Disease Treatment
Year Founded
1987
First Award
1993
Latest Award
2008
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9610 Medical Center Drive Suite 100
Rockville, MD 20850
   (301) 309-6815
   N/A
   www.virionsystems.com
Location: Single
Congr. District: 08
County: Montgomery

Public Profile

Virion Systems, Inc. (VSI) is a Maryland biotechnology corporation focused on the prevention and treatment of infectious diseases, particularly those involving infants and children. Thee firm's core technology is the use of the cotton rat as an animal model of human infectious diseases. Species of cotton rats (genus Sigmodon) have been shown to be permissive for a wide array of human viral, bacterial, rickettsial and parasitic pathogens. Most prominent among these are respiratory syncytial virus (RSV), parainfluenza virus (types 1, 2 and 3), influenza virus (types A and B), adenovirus (various serotypes), poliovirus (types 1, 2 and 3), herpes simplex virus (types 1 and 2) and human immunodeficiency virus (HIV).

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2008 2 NIH $929,309
Project Title: Establishment of HIV Infection in cotton rats
2007 2 NIH $495,021
Project Title: Novel Model to Predict Safety and Efficacy of Microbicides
2006 1 NIH $438,794
Project Title: Treatment of RSV Bronchiolitis with NSAIDs
2003 1 NIH $100,001
Project Title: Mucosal RSV vaccine using CpG oligodeoxynucleotides
1998 1 NIH $100,000
Project Title: Novel Neisseria Meningiditis A And C Conjugate Vaccine

Key People / Management

  Gregory Prince -- President

  Jorge C G Blanco -- Principal

  Marina S Boukhvalova -- Principal

  Marlene K Fischer -- Business Contact